SCHEMBL17199018

SCHEMBL17199018

CS/C(=N\CCc1ccccc1)NS(=O)(=O)N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
LMNA P02545 5/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39
SCN9A Q15858 1/20 0.39
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
AR P10275 1/20 0.37
TSHR P16473 2/20 0.37
HIF1A Q16665 2/20 0.37
SCN5A Q14524 1/20 0.37
SCN2A Q99250 1/20 0.37
SLC22A2 O15244 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25873912 0.76 GRIN1 (0.41) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL9528131 0.75 MAPT (0.45) GAALMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL21675987 0.74 IDO1 (0.51) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL11318413 0.72 SCN5A (0.44) GAALMNAALDH1A1SMN1; SMN2HTT
SCHEMBL11318408 0.72 SCN5A (0.44) GAALMNAALDH1A1SMN1; SMN2HTT
SCHEMBL7896868 0.69 NPY5R (0.50) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL17199015 0.68 RAB9A (0.48) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL9531721 0.68 MAPT (0.44) GAALMNAALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL28902086 0.67 RAB9A (0.47) GAALMNAALDH1A1MEN1KMT2A
Sulfuric Acid SCHEMBL11556093 0.64 GAA (0.62) GAALMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 GAA 604/4885LMNA 2855/4885ALDH1A1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.